Author + information
- Alyavi Anis Lutfullayevich1,
- Alyavi Baxrom Anisxonovich2,
- Uzokov Jamol Kamilovich1,
- Azizov Shuxrat Ismatovich2 and
- Kayumov Nodir Ulugbekovich2
The aim of the present study was to compare the effects of telmisartan combined with amlodipine, versus lisinopril combined with amlodipine, on home blood pressure and pressure variability in hypertensive patients with metabolic syndrome (MS) using home blood pressure monitoring system.
This open-label cross-over pilot study was performed in hypertensive patients with metabolic syndrome. 56 patients were enrolled in this study dividing into two groups by 28. (Aged 42-64 years, mean age of the patients 52±10.6 years, male=46%). Patients received combination treatment with either telmisartan 40 mg plus amlodipine 5 mg or lisinopril 5 mg plus amlodipine 5 mg during the 8 weeks each in a cross-over method. Anthropometric and laboratory data was collected at baseline and after the 8 weeks. Metabolic syndrome was diagnosed by the “Harmonized definition of the MS”. Comparison of variables with a normal distribution and equal variances, we used the t-test for unrelated samples. Statistical calculations were performed in the StatSoft Statistica 10.
The coefficient of morning systolic blood pressure variability in the telmisartan plus amlodipine group was significantly lower than that in the lisinopril plus amlodipine group (7.2±2.0 vs. 8.0±2.4, P<0.05). There were no significant differences in mean morning systolic blood pressure between the two groups respectively: 126.0±14.4 vs. 128.5±12.8 mmHg, P>0.05.
According to the results of this study telmisartan with amlodipine combination is superior to the lisinopril with amlodipine combination in reducing home blood pressure variability in hypertensive patients with metabolic syndrome.